This announcement is made by Peijia Medical Limited (the “ Company”, together with itssubsidiaries, the “ Group”) on a voluntary basis to provide the shareholders of the Companyand potential investors with updated information in relation to the latest business and newproduct development progress of the Group.
The board (the “Board”) of directors (the “Directors”) of the Company is pleased toannounce the successful completion of the first two implants for treating severe aorticregurgitation with the Trilogy™ Transcatheter Heart Valve (“THV”) System in Taiwan,China.
Trilogy™ THV System is a licensed-in CE-Mark approved transcatheter aortic valvereplacement product. It is indicated for use in patients with symptomatic severe aorticregurgitation or symptomatic severe aortic stenosis who are judged by a Heart Team(including a cardiac surgeon), to be at high or greater risk for surgical aortic valvereplacement.
